Laboratory of David Greenberg, M.D.

My overall interests include bacterial pathogenesis in the immunocompromised host as well as new approaches to therapeutics. I am currently involved in projects relating to the Burkholderia cepacia complex (Bcc). These organisms cause disease in patients with Chronic Granulomatous Disease, Cystic Fibrosis and other immunosuppressed patients, such as those with cancer. I have been testing antisense molecules as potential therapeutics in both in vitro and in vivo models of infection with Bcc. Antisense molecules have the potential to be used as therapeutics in other gram-negative and gram-positive bacterial infections. In addition, they can serve as tools to dissect factors important for virulence. In addition we are utilizing transcriptional profiling to better understand factors that may be important in virulence of these organisms.

Significant Publications

Greenberg DE, Marshall-Batty KR, Brinster LR, Zarember KA, Shaw PA, Mellbye BL, Iversen PL, Holland SM, Geller BL, "Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex" Journal of Infectious Diseases, 201(12):1822-30, June 2010

Greenberg DE, Ding L, Zelazny AM, Stock F, Wong A, Anderson VL, Miller G, Kleiner DE, Tenorio AR, Brinster L, Dorward DW, Murray PR, Holland SM., "A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease" PLoS Pathogens, 2(4):e28, April 2006